Impact News +++ 2 Stocks I Like Better Than Constellation Software at Today’s Price (Fool) +++ CONSTELLATION SOFTWARE Aktie +3,15%

VOYAGER THERAPEUTICS Aktie

>Aktienkurs

3.832 EUR +9.1% (Tradegate)

Ask: 3.91 EUR / 1278 Stück

Bid: 3.788 EUR / 5000 Stück

Tagesumsatz: 5443 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: +4,7%

1 Monat: +31,2%

3 Monate: +54,5%

6 Monate: +12,1%

1 Jahr: -25,1%

laufendes Jahr: -30,3%

>VOYAGER THERAPEUTICS Aktie

Name:

VOYAGER THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92915B1061 / A143XJ

Symbol/ Ticker:

VT6 (Frankfurt) / VYGR (NASDAQ)

Kürzel:

FRA:VT6, ETR:VT6, VT6:GR, NASDAQ:VYGR

Index:

Webseite:

https://www.voyagertherap..

Profil:

Voyager Therapeutics Inc. operates as a biotechnol..
>Volltext..

Marktkapitalisierung:

214.24 Mio. EUR

Unternehmenswert:

65.9 Mio. EUR

Umsatz:

36.38 Mio. EUR

EBITDA:

-101.83 Mio. EUR

Nettogewinn:

-92.23 Mio. EUR

Gewinn je Aktie:

-1.58 EUR

Schulden:

34.35 Mio. EUR

Liquide Mittel:

37.55 Mio. EUR

Operativer Cashflow:

-97.12 Mio. EUR

Bargeldquote:

5.14

Umsatzwachstum:

-73.07%

Gewinnwachstum:

-1187.69%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VOYAGER THERAPEUTICS, VOYAGER THERAPEUTIC

Letzte Datenerhebung:

27.09.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 55.47 Mio. St.

Frei handelbar: 82.01%

Leerverk. Aktien: 5.75%

Rückkaufquote: -0.47%

Mitarbeiter: 172

Umsatz/Mitarb.: 0.4 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 258.17%

Bewertung:

KGV: -

KGV lG: -

KUV: 6.25

KBV: 1

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 90.08%

Gewinnmarge: -253.49%

Operative Marge: -289.8%

Managementeffizenz:

Gesamtkaprendite: -28.47%

Eigenkaprendite: -37.26%

>Peer Group

Es sind 600 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

26.08.25 - 13:03	Voyager to Present at Upcoming Investor Conferences (GlobeNewswire EN)
	LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:...

20.08.25 - 22:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Voyager Therapeutics im Wert von 70870 USD (Insiderkauf)
	Ferguson, Toby - Vorstand - Tag der Transaktion: 2025-08-18...

07.08.25 - 01:00	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
	Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

06.08.25 - 23:24	Voyager Therapeutics GAAP EPS of -$0.57 misses by $0.04, revenue of $5.2M misses by $4.3M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.06.25 - 13:06

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire EN)

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference....

15.05.25 - 13:03

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication (GlobeNewswire EN)

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be accessed here....

05.04.25 - 02:01	Insiderhandel: President and CEO verkauft Aktien von Voyager Therapeutics im Wert von 37336 USD (Insiderkauf)
	Sandrock, Alfred - Vorstand - Tag der Transaktion: 2025-04-02...

05.04.25 - 02:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Voyager Therapeutics im Wert von 34595 USD (Insiderkauf)
	Ferguson, Toby - Vorstand - Tag der Transaktion: 2025-04-02...

17.03.25 - 20:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR (PR Newswire)
	NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

12.03.25 - 22:15	A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts (Benzinga)
	Latest Ratings for VYGR DateFirmActionFromTo Nov 2021Chardan CapitalMaintainsNeutral Oct 2021BairdUpgradesNeutralOutperform Jun 2021Compass PointInitiates Coverage OnBuy View More Analyst Ratings for VYGR View the Latest Analyst Ratings read more...

12.03.25 - 00:00	Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
	Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

11.03.25 - 21:06	Voyager Therapeutics GAAP EPS of -$0.59 misses by $0.21, revenue of $6.28M misses by $10.3M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.03.25 - 17:21	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR (PR Newswire)
	NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

10.03.25 - 22:42	Voyager Therapeutics Q4 2024 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.03.25 - 13:03	Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast (GlobeNewswire EN)
	LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET....

03.03.25 - 20:42	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR (PR Newswire)
	NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

25.02.25 - 23:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR (PR Newswire)
	NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

25.02.25 - 00:01	Insiderhandel: Chief Scientific Officer verkauft Aktien von Voyager Therapeutics im Wert von 14079 USD (Insiderkauf)
	Carter, Todd Alfred - Vorstand - Tag der Transaktion: 2025-02-20...

25.02.25 - 00:01	Insiderhandel: President and CEO verkauft Aktien von Voyager Therapeutics im Wert von 49616 USD (Insiderkauf)
	Sandrock, Alfred - Vorstand - Tag der Transaktion: 2025-02-20...

25.02.25 - 00:01	Insiderhandel: COO & CBO verkauft Aktien von Voyager Therapeutics im Wert von 16550 USD (Insiderkauf)
	Swartz, Robin - Vorstand - Tag der Transaktion: 2025-02-20...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Unmöglich ist′s, drum eben glaubenswert. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram